Free Trial
NASDAQ:PTCT

PTC Therapeutics (PTCT) Stock Price, News & Analysis

PTC Therapeutics logo
$61.09 +0.13 (+0.21%)
Closing price 09/12/2025 04:00 PM Eastern
Extended Trading
$61.11 +0.02 (+0.03%)
As of 09/12/2025 07:56 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

About PTC Therapeutics Stock (NASDAQ:PTCT)

Key Stats

Today's Range
$60.48
$62.18
50-Day Range
$43.30
$61.09
52-Week Range
$33.19
$62.18
Volume
1.76 million shs
Average Volume
1.28 million shs
Market Capitalization
$4.85 billion
P/E Ratio
8.76
Dividend Yield
N/A
Price Target
$69.00
Consensus Rating
Moderate Buy

Company Overview

PTC Therapeutics Stock Analysis - MarketRank™

See Top-Rated MarketRank™ Stocks
73rd Percentile Overall Score

PTCT MarketRank™: 

PTC Therapeutics scored higher than 73% of companies evaluated by MarketBeat, and ranked 301st out of 958 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

  • Consensus Rating

    PTC Therapeutics has received a consensus rating of Moderate Buy. The company's average rating score is 2.53, and is based on 9 buy ratings, 5 hold ratings, and 1 sell rating.

  • Upside Potential

    PTC Therapeutics has a consensus price target of $69.00, representing about 12.9% upside from its current price of $61.09.

  • Amount of Analyst Coverage

    PTC Therapeutics has been the subject of 10 research reports in the past 90 days, demonstrating strong analyst interest in this stock.

  • Read more about PTC Therapeutics' stock forecast and price target.
  • Earnings Growth

    Earnings for PTC Therapeutics are expected to decrease in the coming year, from ($4.52) to ($4.69) per share.

  • Price to Earnings Ratio vs. the Market

    The P/E ratio of PTC Therapeutics is 8.76, which means that it is trading at a less expensive P/E ratio than the market average P/E ratio of about 280.69.

  • Price to Earnings Ratio vs. Sector

    The P/E ratio of PTC Therapeutics is 8.76, which means that it is trading at a less expensive P/E ratio than the Medical sector average P/E ratio of about 74.86.

  • Read more about PTC Therapeutics' valuation and earnings.
  • Percentage of Shares Shorted

    8.85% of the float of PTC Therapeutics has been sold short.
  • Short Interest Ratio / Days to Cover

    PTC Therapeutics has a short interest ratio ("days to cover") of 5.5.
  • Change versus previous month

    Short interest in PTC Therapeutics has recently increased by 2.15%, indicating that investor sentiment is decreasing.
  • Dividend Yield

    PTC Therapeutics does not currently pay a dividend.

  • Dividend Growth

    PTC Therapeutics does not have a long track record of dividend growth.

  • Percentage of Shares Shorted

    8.85% of the float of PTC Therapeutics has been sold short.
  • Short Interest Ratio / Days to Cover

    PTC Therapeutics has a short interest ratio ("days to cover") of 5.5.
  • Change versus previous month

    Short interest in PTC Therapeutics has recently increased by 2.15%, indicating that investor sentiment is decreasing.
  • News Sentiment

    PTC Therapeutics has a news sentiment score of 1.00. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This news sentiment score is similar to the average news sentiment of Medical companies.
  • News Coverage This Week

    MarketBeat has tracked 19 news articles for PTC Therapeutics this week, compared to 9 articles on an average week.
  • Search Interest

    Only 3 people have searched for PTCT on MarketBeat in the last 30 days. This is a decrease of -63% compared to the previous 30 days.
  • MarketBeat Follows

    Only 1 people have added PTC Therapeutics to their MarketBeat watchlist in the last 30 days. This is a decrease of 0% compared to the previous 30 days.
  • Insider Buying vs. Insider Selling

    In the past three months, PTC Therapeutics insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $3,815,619.00 in company stock.

  • Percentage Held by Insiders

    Only 5.50% of the stock of PTC Therapeutics is held by insiders.

  • Read more about PTC Therapeutics' insider trading history.
Receive PTCT Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for PTC Therapeutics and its competitors with MarketBeat's FREE daily newsletter.

By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

PTCT Stock News Headlines

PTC Therapeutics (NASDAQ:PTCT) Director Sells $700,080.00 in Stock
2013 Bitcoin miner reveals his trading system (free)
While everyone else is gambling on meme coins or chasing the next "100x moonshot," our members are systematically extracting profits from the $4 billion that changes hands in crypto every single day.tc pixel
PTC Therapeutics, Inc. (PTCT) Launches SUFIANCE for PKU
See More Headlines

PTCT Stock Analysis - Frequently Asked Questions

PTC Therapeutics' stock was trading at $45.14 at the start of the year. Since then, PTCT stock has increased by 35.3% and is now trading at $61.09.

PTC Therapeutics, Inc. (NASDAQ:PTCT) issued its quarterly earnings results on Thursday, August, 7th. The biopharmaceutical company reported ($0.83) earnings per share (EPS) for the quarter, topping analysts' consensus estimates of ($1.07) by $0.24. PTC Therapeutics's revenue was down 4.2% on a year-over-year basis.
Read the conference call transcript
.

Top institutional investors of PTC Therapeutics include Armistice Capital LLC (5.96%), State Street Corp (3.77%), Geode Capital Management LLC (2.44%) and Man Group plc (0.85%). Insiders that own company stock include Matthew B Klein, Stuart Walter Peltz, Michael Schmertzler, Mark Elliott Boulding, Neil Gregory Almstead, Lee Scott Golden, Eric Pauwels, Pierre Gravier, Christine Marie Utter, Emily Luisa Hill, Allan Steven Jacobson, David P Southwell, Jerome B Zeldis, Alethia Young, Stephanie Okey and Emma Reeve.
View institutional ownership trends
.

Shares of PTCT stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

Based on aggregate information from My MarketBeat watchlists, some other companies that PTC Therapeutics investors own include Tesla (TSLA), NVIDIA (NVDA), Meta Platforms (META), Netflix (NFLX), Advanced Micro Devices (AMD), JPMorgan Chase & Co. (JPM) and Home Depot (HD).

Company Calendar

Last Earnings
8/07/2025
Today
9/13/2025
Next Earnings (Estimated)
11/06/2025
Fiscal Year End
12/31/2025

Industry, Sector and Symbol

Stock Exchange
NASDAQ
Sector
Medical
Industry
MED - BIOMED/GENE
Sub-Industry
Pharmaceutical Products
Current Symbol
NASDAQ:PTCT
CIK
1070081
Employees
1,410
Year Founded
1998

Price Target and Rating

High Price Target
$118.00
Low Price Target
$42.00
Potential Upside/Downside
+12.9%
Consensus Rating
Moderate Buy
Rating Score (0-4)
2.53
Research Coverage
15 Analysts

Profitability

EPS (Trailing Twelve Months)
$6.97
Trailing P/E Ratio
8.76
Forward P/E Ratio
N/A
P/E Growth
N/A
Net Income
-$363.30 million
Net Margins
35.65%
Pretax Margin
37.74%
Return on Equity
-106.31%
Return on Assets
30.61%

Debt

Debt-to-Equity Ratio
N/A
Current Ratio
3.62
Quick Ratio
3.57

Sales & Book Value

Annual Sales
$806.78 million
Price / Sales
6.02
Cash Flow
N/A
Price / Cash Flow
N/A
Book Value
($14.24) per share
Price / Book
-4.29

Miscellaneous

Outstanding Shares
79,440,000
Free Float
75,069,000
Market Cap
$4.85 billion
Optionable
Optionable
Beta
0.53

Social Links

A Guide To High-Short-Interest Stocks Cover

MarketBeat's analysts have just released their top five short plays for September 2025. Learn which stocks have the most short interest and how to trade them. Enter your email address to see which companies made the list.

Get This Free Report

This page (NASDAQ:PTCT) was last updated on 9/13/2025 by MarketBeat.com Staff
From Our Partners